NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy

• Published in: Clinical cancer research Vol. 28; no. 7; pp. 1460 - 1473
• Main Authors: Otani, Yoshihiro, Yoo, Ji Young, Lewis, Cole T., Chao, Samantha, Swanner, Jessica, Shimizu, Toshihiko, Kang, Jin Muk, Murphy, Sara A., Rivera-Caraballo, Kimberly, Hong, Bangxing, Glorioso, Joseph C., Nakashima, Hiroshi, Lawler, Sean E., Banasavadi-Siddegowda, Yeshavanth, Heiss, John D., Yan, Yuanqing, Pei, Guangsheng, Caligiuri, Michael A., Zhao, Zhongming, Chiocca, E. Antonio, Yu, Jianhua, Kaur, Balveen
• Format: Journal Article
• Language: English
• Published: United States 01.04.2022
• Subjects: Animals; Cell Line, Tumor; Glioblastoma - pathology; Humans; Immunotherapy; Mice; Myeloid-Derived Suppressor Cells - metabolism; Neoplasm Recurrence, Local - therapy; Oncolytic Virotherapy - methods; Oncolytic Viruses - genetics; Simplexvirus; Tumor Microenvironment; Xenograft Model Antitumor Assays

Oncolytic herpes simplex virus-1 (oHSV) infection of brain tumors activates NOTCH, however the consequences of NOTCH on oHSV-induced immunotherapy is largely unknown. Here we evaluated the impact of NOTCH blockade on virus-induced immunotherapy. RNA sequencing (RNA-seq), TCGA data analysis, flow cyt...